Top Markets
Coin of the day
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Rang in Aktien #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Aktienkurs
$1.11
Zuletzt synchronisiert: 2026-08-21
Marktkapitalisierung
$100.55M
Veränderung (1 Tag)
-7.69%
Veränderung (1 Jahr)
-7.17%
Land
TW
Handel Senhwa Biosciences, Inc. (6492)

Kategorie

Preis 6492 mit Marktkapitalisierung von B
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
6492
$1.11
Marktkapitalisierung von Senhwa Biosciences, Inc.(6492)
Marktkapitalisierung: $100.55M
Mit Stand August 2026 hat Senhwa Biosciences, Inc. eine Marktkapitalisierung von $100.55M. Das macht Senhwa Biosciences, Inc. laut unseren Daten zum 21774th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Senhwa Biosciences, Inc. von 2014 bis 2026
6492 im Vergleich zu den Top 5 der beliebtesten stocks
Preis für 6492 Vermögenswert B Marktkapitalisierung von B Ergebnisse
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$57,355.39 $100.55M
$5.211T +5,182,899.16%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$50,040.67 $100.55M
$4.547T +4,521,894.34%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$45,811.46 $100.55M
$4.162T +4,139,716.21%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$39,541.61 $100.55M
$3.593T +3,573,132.23%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$30,737.65 $100.55M
$2.793T +2,777,550.53%